Girentuximab companion diagnostic - Wilex/Nuclea Biotechnologies

Drug Profile

Girentuximab companion diagnostic - Wilex/Nuclea Biotechnologies

Alternative Names: CAIX Dx; CAIX ELISA/IHC test

Latest Information Update: 12 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncogene Science; WILEX AG
  • Developer Nuclea Biotechnologies; WILEX AG
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Renal cell carcinoma

Most Recent Events

  • 06 Sep 2013 Nuclea Biotechnologies acquires Wilex Oncogene Science
  • 11 Jul 2013 Clinical trials in Renal cell carcinoma (diagnosis) in USA (in vitro)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top